Trial Profile

Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary) ; Toripalimab (Primary) ; Irinotecan; Paclitaxel
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

04 Apr 2024 Results (n=26) assessing safety and efficacy of Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer published in the Oncologist
13 Sep 2022 Results (n=52) assessing the combination of toripalimab and apatinib as second-line treatment for advanced gastric/oesophageal cancer presented at the 47th European Society for Medical Oncology Congress.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com